Mitsubishi Heavy Industrial Develops New Cancer Treatment Device
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Heavy Industrial has developed a new X-ray cancer treatment device that scans and radiates affected areas. The equipment is jointly developed with Kyodo University and the Kobe-based Institute of Biomedical Research and Innovation and will be sold in Japan, the E.U. and the U.S. The device uses X-ray technology to scan cancer cells, processes information on the cancer position through computers, and then radiates the area with an oscillating X-ray head based on the processed information. Because of the high level of accuracy, Mitsubishi stated that the radiation therapy would reduce the occurrence of side effects and shorten treatment time. (Click here for more-Japanese language
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.